Skip to content
RNAWiki

Carbidopa Anhydrous

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Carbidopa Anhydrous does in the body

Carbidopa is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

From the FDA-approved label: Current evidence indicates that symptoms of Parkinson's disease are related to depletion of dopamine in the corpus striatum. Administration of dopamine is ineffective in the treatment of Parkinson's disease apparently because it does not cross the blood-brain barrier. However, levodopa, the metabolic precursor of dopamine, does cross the blood-brain barrier, and presumably is converted to dopamine in the brain. This is thought to be the mechanism whereby levodopa relieves symptoms of Parkinson's disease.

Why people take it. Carbidopa is indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · MNX7R8C5VO · read 2026-08-29

  • Its recorded molecular formula is C10H14N2O4•H2O, weighing 244.24.

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

Where each sentence above came from

The use the label states, quoted from it. No plain-language version of this sentence has been written.

The use the label states, quoted from it. It is written for a clinician, not for a reader without medical training.

No statement of the main limit is recorded.

The four opening statements run to 174 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Formulation

A formulation is the exact made-up form a substance comes in.

A picture of it, and where the picture fails

It is like the difference between a whole bean and instant coffee.

Where that stops being true. Coffee tastes different. A formulation can change how much reaches the blood.

What people get wrong. Two products with the same name are assumed to behave the same. They often do not.

The specific composition and physical form of a product, including salt, excipients and release profile.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

Time to First Occurrence of Dyskinesia

The study did not show it

Who was studied
NCT00099268
How many people
747
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET)

The study did not show it

Who was studied
NCT03670953
How many people
630
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III

The study did not show it

Who was studied
NCT01096186
How many people
617
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change From Baseline in the Total Hours of Awake Time/Day Spent in the OFF State at Week 12

The study did not show it

Who was studied
NCT01968031
How many people
613
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Fugl-Meyer-Motor Assessment Score (FMMA)

The study did not show it

Who was studied
NCT03735901
How many people
610
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Efficacy of 3 BIA 9-1067 (5 mg, 25 mg, and 50 mg) Compared With 200 mg of Entacapone or Placebo,

The study did not show it

Who was studied
NCT01568073
How many people
600
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication.

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Safety and effectiveness in pediatric patients have not been established, and use of the drug in patients below the age of 18 is not recommended.”

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

  • On older people, the label states: “Clinical studies of carbidopa did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.”

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

  • On people who are pregnant, the label states: “Category C: There are no adequate and well-controlled studies with carbidopa in pregnant women.”

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

  • On people who are breastfeeding, the label states: “It is not known whether carbidopa is excreted in human milk.”

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

A different form was studied

The studied form is not the form on the shelf.

On this record: This record is linked to 1 related forms. Evidence does not carry across all of them.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

RNAWiki has not recorded a supervision or regulatory status for this substance.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

No register row and no identity class settled the question.

No source is stored against this line.

What is in the pack

Sold as tablet, tablet, extended release, tablet, orally disintegrating, capsule, extended release, given by the oral, enteral route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 178 products list this as an active ingredient in the United States drug directory. 24 of them contain it and nothing else.

    FDA National Drug Code directory · 72865-361 · read 2026-08-29

  • They are sold as capsule, extended release, powder, suspension, tablet, tablet, extended release and tablet, film coated, taken enteral and oral.

    FDA National Drug Code directory · 72865-361 · read 2026-08-29

  • 80 published labels name it as an active ingredient. 9 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 87ab55c9-203d-d595-3e3e-0e38f2f6d9c4 · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 87ab55c9-203d-d595-3e3e-0e38f2f6d9c4 · read 2026-08-29

  • 8 marketed supplement labels list this ingredient, classed as botanical with nutrients, non-nutrient/non-botanical, other combinations and vitamin.

    NIH Dietary Supplement Label Database · 208639 · read 2026-08-29

  • Those labels carry all other, nutrient and structure/function claims. A claim of that kind is written by the manufacturer and is not assessed by any regulator, so its presence says nothing about whether it is true.

    NIH Dietary Supplement Label Database · 208639 · read 2026-08-29

  • CARBIDOPA is oral at HOW SUPPLIED Carbidopa Tablets 25 mg, are mottled orange round uncoated tablet debossed "1221" on flat side and scored on convex side and are supplied as: NDC 70710-1221-1 in bottle of 100 tablets Storage Store at 25°C…, recorded as fda label in effect 2023-09-16 in the United States.

    US prescribing information · c0b1ef99-3092-431a-8fb6-897affd52595 · read 2026-08-30

  • Recorded price in US: 0.53249 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 4 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

Names and forms linked to this record

  • Stereoisomer of

    Carbidopa, Levodopa

    Evidence on this page does not automatically apply to this one.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.

Questions worth asking

  • Which of the trials of Carbidopa Anhydrous studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Carbidopa Anhydrous are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

Where else this substance is registered

FDA substance identifier (UNII)
MNX7R8C5VO
RxNorm concept
260260

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Quoted from a stored source.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Not passed

    Safety mode resolved

    No register row and no identity class settled the question.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 56 approved applications cover products containing this substance. The earliest was NDA017555, approved 19750502 to ORGANON.

    Drugs@FDA application register · NDA017555 · read 2026-08-29

  • Marketing status on the register: discontinued, none (tentative approval) and prescription.

    Drugs@FDA application register · NDA017555 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19820101.

    FDA National Drug Code directory · 72865-361 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

9 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • What was measured, goal by goal — found nothing in the sources checked.
  • How close this is to real life — found nothing in the sources checked.
  • The path through the body — found nothing in the sources checked.
  • Felt, measured, or meaningful — found nothing in the sources checked.
  • How long anything takes — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (8)

On the Carbidopa Anhydrous label: indicated for what?

"Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or…": indications and usage on Carbidopa Anhydrous's label. DailyMed label · 55b99f22-9eb2-4df6-9979-bc4c3af5e454 · 2025-12-17

49 registered trials of Carbidopa Anhydrous — at which phases?

Registered studies posting no result
29 of 49

49 registered studies of Carbidopa Anhydrous: 20 phase2, 18 phase1, 11 phase3, 8 phase4, 1 na. CLINICALTRIALS_SNAPSHOT · 2026-09-01

500 with a PubMed record

Show the evidence
  • phase2
    20
  • phase1
    18
  • phase3
    11
  • phase4
    8
  • na
    1
  • completed
    38
5 more recorded rows
  • unknown
    3
  • withdrawn
    3
  • recruiting
    2
  • terminated
    2
  • suspended
    1

recorded 2026-09-01 · last checked 2026-09-04

6 of Carbidopa Anhydrous's trials stopped: accrual/recruitment, other?

accrual/recruitment (3) and other (3): Carbidopa Anhydrous's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01

"Study terminated due to contamination droxidopa"; 6 of 49 registered studies

Show the evidence

Trial

  • NCT00547911
    terminated; "Study terminated due to contamination droxidopa"
  • NCT00601978
    withdrawn; "Business decision brand strategy; no patients enrolled"
  • NCT00642356
    terminated; "slow enrollment"
  • NCT04000919
    suspended; "PI left UofL and intends to reopen study at University of Alberta"
  • NCT04764383
    withdrawn; "Withdrawn as more data drug analysis is recommended before the study."
  • NCT05087914
    withdrawn; "Study was not started, therefore recruitment did not happen"

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Carbidopa Anhydrous used capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg) — over how long?

Human studies of Carbidopa Anhydrous used "capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)". ClinicalTrials.gov · 2026-09-01

9 recorded entries; human; oral; also "ODM-101 65mg Carbidopa", "ODM-101 105mg Carbidopa", "Rytary 195 mg"

Show the evidence

human

  • NCT00134966
    capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)
  • NCT01766258
    ODM-101 65mg Carbidopa
  • NCT01766258
    ODM-101 105mg Carbidopa
  • NCT02271503
    Rytary 195 mg
  • NCT02271503
    Rytary 145 mg
  • NCT04246437
    oral; Carbidopa 200mg oral dose
3 more recorded rows
  • human NCT05087914
    Carbidopa-Levodopa (100mg/25mg):
  • human NCT06219915
    Carbidopa 25 mg
  • human NCT06219915
    Carbidopa-Levodopa 25/100 mg

recorded 2026-09-01 · last checked 2026-09-04

Which 20 trials of Carbidopa Anhydrous posted no result?

Posted no result
20 of 20 completed trials
Registrations
NCT00200447, NCT00134966, NCT00218075, NCT00462007, NCT00125567 and NCT00914602, and 14 more
Completion dates
oldest 2004-09; newest 2023-12-05
Show the evidence

Trial

  • NCT00200447
    2004-09
  • NCT00134966
    2007-09
  • NCT00218075
    2007-10
  • NCT00462007
    2007-12
  • NCT00125567
    2009-03
  • NCT00914602
    2010-01
14 further recorded trials
  • NCT01070628
    2010-02
  • NCT01296464
    2011-07
  • NCT01323374
    2011-10
  • NCT01229332
    2011-11
  • NCT01766258
    2012-09
  • NCT02554734
    2015-11
  • NCT02633007
    2016-05
  • NCT02633839
    2016-06
  • NCT02271503
    2016-08
  • NCT00223717
    2017-01
  • NCT02764125
    2018-03-27
  • NCT03205956
    2019-10-19
  • NCT03266965
    2020-08-07
  • NCT06161220
    2023-12-05

At the median, Carbidopa Anhydrous's trials enrolled 30 people — anything larger?

Median enrolment
30
Largest enrolment
747
Registered trials counted
49

What do 2327 spontaneous reports say about Carbidopa Anhydrous — and not say?

These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Carbidopa Anhydrous appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 2327 reaction mentions were counted: dyskinesia 386; fall 326; hallucination 305; tremor 277. FAERS via Open Targets · CHEMBL1200748 · 2026-06-24

Show the evidence
  • dyskinesia
    386
  • fall
    326
  • hallucination
    305
  • tremor
    277
  • confusional state
    239
  • parkinson's disease
    214
4 more recorded rows
  • gait disturbance
    166
  • somnolence
    145
  • anxiety
    139
  • hallucination, visual
    130

recorded 2026-06-24 · last checked 2026-09-04

Which 10 reactions does Carbidopa Anhydrous's label not list?

anxiety, confusional state and dyskinesia and 7 more reported for Carbidopa Anhydrous, absent from its label. FAERS via Open Targets · CHEMBL1200748 · 2026-06-24

2 label terms; 10 reported and unlisted; 55b99f22-9eb2-4df6-9979-bc4c3af5e454

Show the evidence
  • anxiety
    count not stated
  • confusional state
    count not stated
  • dyskinesia
    count not stated
  • fall
    count not stated
  • gait disturbance
    count not stated
  • hallucination
    count not stated
4 more recorded rows
  • hallucination, visual
    count not stated
  • parkinson's disease
    count not stated
  • somnolence
    count not stated
  • tremor
    count not stated

recorded 2026-06-24 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL1200748
PubChem CID
38101
CAS number
38821-49-7
RxCUI
2019
InChIKey
TZFNLOMSOLWIDK-JTQLQIEISA-N

Relations

Also called
Carbidopa
Also called
Carbidopa component of carbilev, Carbidopa component of parcopa, Carbidopa component of sinemet, carbidopa-levodopa, cd, cd-ld ir, ipx054, lcig, levodopa/carbidopa, nd0612, sinemet cr, wd-1603
Trade name
Carbidopa component of corbilta, Carbidopa component of crexont, Carbidopa component of dhivy, Carbidopa component of dopasnap, Carbidopa component of duopa, Carbidopa component of ipx-203, Carbidopa component of levodopa//entacapone orion, Carbidopa component of rytary, Carbidopa component of stalevo, Lodosyn, Rytary, Crexont
Salt form
Carbidopa hydrate, Carbidopa monohydrate, Carbidopum monohydrate, levodopa-carbidopa immediate release (ir) active capsules, Carbidopa, l- anhydrous, CARBIDOPA TABLETS
Development code
MK-486, NSC-751137, NSC-758190
Component
Carbidopa
Sources (6)

Sources

ChEMBL 37 — CC BY-SA 3.0 Unported · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 6 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.